

## Hematology

Measure #2: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in



**Measure Specifications** – Measure #2: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy

**Administrative Claims/Registry**

Administrative claims data collection requires users to identify the eligible population (denominator) and numerator using codes recorded on claims or billing forms (electronic or paper). Users report a rate based on all patients in a given practice for whom data are available and who meet the eligible population/denominator criteria.

Denominator (Eligible Population): All patients aged 18 years and older with a diagnosis of myelodysplastic syndrome (MDS) who are receiving erythropoietin therapy

Patients aged 18 years on date of encounter

**AND**

## EVIDENCE CLASSIFICATIONS / RATING SCHEMES

National Comprehensive Cancer Network (NCCN) Recommendation Rating Scale<sup>1</sup> - - - -

Category of Consensus	Quality of Evidence	Level of Consensus
1	High	Uniform
2A	Lower	Uniform
2B	Lower	Non-uniform
3	Any	Major disagreement

Category 1: 33333t{s6aZ -0ZZ -)-3.

recognizes that given imperfect information, institutions may adopt different approaches. A Category 2B designation should signal to the user that more than one approach can be inferred from the existing data.

**Category 3:** Including the recommendation AssInudyn2 (6 (a)-3.2)Tj-0.004 Tc 0.004 Tw848 -1.2